Status Plus

abstract

abstract

524

Vaccinating male individuals against human papillomavirus - an evidence-based review

Dias, J1; Lima, E1

1: USF Arca D'Água, Portugal

Objective: To formulate evidence based recommendations on vaccinating male individuals against human papillomavirus (HPV).

Materials and methods: A research with the keywords “hpv”, “vaccination” and “men” was performed for published articles on the last ten years, on Portuguese and English languages, on the following data bases: PubMed, National Guidelines Cleringhouse, Guidelines Finder, CMA Infobase, Cochrane, DARE and BMJ. Thirteen documents were obtained and the recommendations’ analysis was conducted according to the Strength Of Recommendation Taxonomy (SORT) system.

Results: From the five reviews, seven consensus and one guideline that were found, the following recommendations on vaccinating male individuals against HPV were obtained. Routine vaccination should be performed on all individuals at 11 or 12 years old (C). Vaccination is recommended until the age of 21 years old, if not vaccinated previously (C). Vaccination of men who have sex with men (MSM) is recommended until the age of 26 years old (B). Vaccination is recommended on all immunocompromised individuals (B). Vaccination is recommended on all HIV-infected individuals (B).

Conclusions: None of the analyzed documents is a randomized clinical trial, which would provide a higher strength of recommendation, so the majority of the current recommendations are based on experts’ or scientific societies’ consensus. More studies are required to clarify the benefit of vaccinating male individuals against HPV, as well as cost-effectiveness studies, given the cost of the available vaccines. The age and timings of vaccination recommended differ among the obtained literature. Nevertheless, HPV vaccination seems universally recommended, and more beneficial, for MSM and HIV-infected individuals.

Disclosure:

Work supported by industry: no.

Go Back